Shayzreen Roshanravan, MD
Urogynecology and Reconstructive Pelvic Surgery · Plano, TXNPI 1861502627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Astellas Pharma US Inc at 31.0% of the total. Reporting peaked in 2021 at $529 and has fallen 72.6% since, to $145 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TX, where the typical reported total is $5,014.
Across 90 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$590
- Axonics, Inc.$405
- Urovant Sciences Inc$134
- Caldera Medical, Inc$129
- Boston Scientific$118
- AbbVie$110
- plus $419 from 12 others
What the payments were for
- Food & beverage$1,76393%
- Education$1417%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 30 | $590 |
| Axonics, Inc. | 21 | $405 |
| Urovant Sciences Inc | 6 | $134 |
| Caldera Medical, Inc | 3 | $129 |
| Boston Scientific | 6 | $118 |
| AbbVie(2 entities) | 6 | $110 |
| Millicent US Inc | 2 | $88 |
| 180 Medical, Inc. | 3 | $69 |
| Convatec Inc. | 2 | $51 |
| Avation Medical, Inc. | 1 | $49 |
| Pfizer | 2 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Mission Pharmacal Company | 2 | $26 |
| Medtronic | 1 | $18 |
| Allegis Pharmaceuticals, LLC | 1 | $14 |
| Hollister Incorporated | 1 | $13 |
| Valencia Technologies Corporation | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$103
How this compares
$1,904 in reported general payments places this provider in the 20th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 23 | $13,861 |
| Estradiol | 136 | $8,086 |
| Trospium Chloride | 33 | $2,137 |
| Methenamine Hippurate | 18 | $1,962 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $560 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $103 |
| Triamcinolone Acetonide | 13 | $84 |
| Tramadol Hcl | 26 | $53 |
| Fluconazole | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $590 | $13,86123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Plano
- Amit PatelPlano$12K
- J MathewsPlano$3K
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.